Ariad Pharmaceuticals Inc fka ARIA

[Sikmarson]

Houston,Texas,USA September15-18,2016 18th Annual John Goldman Conf.

Long-term efficacy and safety of ponatinib in heavily pretreated leukemia patients: 4-year results from the pivotal phase 2 PACE trial
-Jorge Cortes (Houston)

Impact of early responses on 3-year outcomes in heavily pretreated CP-CML patients: landmark analyses in the pivotal ponatinib PACE trial
-Martin C.Müller (Mannheim)

preliminary program


ESMO,Copenhagen,Denmark October 07-11, Annual Congress 2016

-ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib versus crizotinib in TKI–naive, advanced ALK–positive NSCLC
(Camidge, Kerstein...)

-Brigatinib in patients with ALK–positive NSCLC in a phase 1/2 trial
(Camidge, Kerstein, Haluska...)

preliminary program